Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib

被引：3
|
作者：
Sigmund, Audrey M. [1 ]
Huang, Ying [1 ]
Ruppert, Amy S. [1 ]
Maddocks, Kami [1 ]
Rogers, Kerry A. [1 ]
Jaglowski, Samantha [1 ]
Bhat, Seema A. [1 ]
Kittai, Adam S. [1 ]
Grever, Michael R. [1 ]
Byrd, John C. [1 ,2 ]
Woyach, Jennifer A. [1 ]
机构：
[1] Ohio State Univ, Div Hematol, Columbus, OH 43210 USA
[2] Univ Cincinnati, Dept Internal Med, Cincinnati, OH USA
来源：
LEUKEMIA | 2022年 / 36卷 / 08期
关键词：
OFATUMUMAB; THERAPY; DISEASE; BTK;
D O I：
10.1038/s41375-022-01640-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：2129 / 2131
页数：3
相关论文
共 50 条
  • [1] Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib
    Audrey M. Sigmund
    Ying Huang
    Amy S. Ruppert
    Kami Maddocks
    Kerry A. Rogers
    Samantha Jaglowski
    Seema A. Bhat
    Adam S. Kittai
    Michael R. Grever
    John C. Byrd
    Jennifer A. Woyach
    [J]. Leukemia, 2022, 36 : 2129 - 2131
  • [2] Depth of Response and Progression-Free Survival in CLL Patients on Ibrutinib
    不详
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (07) : 8 - 9
  • [3] Complete Response Linked to Progression-Free Survival in Chronic Lymphocytic Leukemia
    Schuyler, Devon
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 92 - 92
  • [4] The Addition of Rituximab to Fludarabine and Cyclophosphamide Improves Progression-free Survival in Patients with Previously Treated Chronic Lymphocytic Leukemia
    Amit Mahipal
    Mark Weiss
    [J]. Current Oncology Reports, 2010, 12 : 352 - 354
  • [5] The Addition of Rituximab to Fludarabine and Cyclophosphamide Improves Progression-free Survival in Patients with Previously Treated Chronic Lymphocytic Leukemia
    Mahipal, Amit
    Weiss, Mark
    [J]. CURRENT ONCOLOGY REPORTS, 2010, 12 (06) : 352 - 354
  • [6] RELATIONSHIP BETWEEN PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA
    Beauchemin, C.
    Johnston, J.
    Lapierre, M. E.
    Aissa, F.
    Lachaine, J.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A414 - A415
  • [7] RELATIONSHIP BETWEEN PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA
    Beauchemin, C.
    Johnston, J. B.
    Lapierre, M.
    Aissa, F.
    Lachaine, J.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 350 - 350
  • [8] Response, Progression-Free Survival, and Overall Survival of patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities
    Woyach, Jennifer A.
    Ruppert, Amy S.
    Blum, Kristie A.
    Jones, Jeffrey Alan
    Flynn, Joseph M.
    Johnson, Amy J.
    Grever, Michael R.
    Byrd, John C.
    Heerema, Nyla A.
    [J]. BLOOD, 2010, 116 (21) : 1019 - 1020
  • [9] Depth of response and progression free survival in CLL patients on ibrutinib.
    Sigmund, Audrey
    Huang, Ying
    Ruppert, Amy S.
    Ny, Fan
    Lucas, Margaret
    Chase, Weihong
    Maddocks, Kami J.
    Rogers, Kerry Anne
    Jaglowski, Samantha Mary
    Andritsos, Leslie Ann
    Awan, Farrukh Tauseef
    Grever, Michael R.
    Byrd, John C.
    Woyach, Jennifer Ann
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab
    Awan, Farrukh T.
    Kay, Neil E.
    Davis, Melanie E.
    Wu, Wenting
    Geyer, Susan M.
    Leung, Nelson
    Jelinek, Diane F.
    Tschumper, Renee C.
    Secreto, Charla R.
    Lin, Thomas S.
    Grever, Michael R.
    Shanafelt, Tait D.
    Zent, Clive S.
    Call, Timothy G.
    Heerema, Nyla A.
    Lozanski, Gerard
    Byrd, John C.
    Lucas, David M.
    [J]. BLOOD, 2009, 113 (03) : 535 - 537
12345